239 related articles for article (PubMed ID: 19171109)
1. Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs.
Hermann M
Curr Rheumatol Rep; 2009 Feb; 11(1):31-5. PubMed ID: 19171109
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
Minhas D; Nidhaan A; Husni ME
Rheum Dis Clin North Am; 2023 Feb; 49(1):179-191. PubMed ID: 36424024
[TBL] [Abstract][Full Text] [Related]
3. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
[TBL] [Abstract][Full Text] [Related]
4. [What do we know about the cardiovascular toxicity of the NSAIDs?].
Sibilia J; Deray G; Montalescot G
Presse Med; 2006 Sep; 35(9 Spec No 1):1S11-23. PubMed ID: 17078591
[TBL] [Abstract][Full Text] [Related]
5. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.
Maillard M; Burnier M
Expert Opin Drug Saf; 2006 Jan; 5(1):83-94. PubMed ID: 16370958
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
7. Cardiorenal Safety of OTC Analgesics.
White WB; Kloner RA; Angiolillo DJ; Davidson MH
J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):103-118. PubMed ID: 29421936
[TBL] [Abstract][Full Text] [Related]
8. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
9. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Prozzi GR; Cañás M; Urtasun MA; Buschiazzo HO; Dorati CM; Mordujovich-Buschiazzo P
Medicina (B Aires); 2018; 78(5):349-355. PubMed ID: 30285927
[TBL] [Abstract][Full Text] [Related]
10. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
[TBL] [Abstract][Full Text] [Related]
11. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
Prescrire Int; 2016 Jan; 25(167):14-6. PubMed ID: 26942254
[TBL] [Abstract][Full Text] [Related]
12. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk of non-steroidal anti-inflammatory drugs.
Alušík Š; Paluch Z
Vnitr Lek; 2018; 64(3):266-271. PubMed ID: 29766729
[TBL] [Abstract][Full Text] [Related]
15. COX-2 selective inhibitors in the treatment of osteoarthritis.
Laine L; White WB; Rostom A; Hochberg M
Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
[TBL] [Abstract][Full Text] [Related]
17. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
[TBL] [Abstract][Full Text] [Related]
19. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
Konstantinopoulos PA; Lehmann DF
J Clin Pharmacol; 2005 Jul; 45(7):742-50. PubMed ID: 15951464
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
Pelletier JP; Martel-Pelletier J; Rannou F; Cooper C
Semin Arthritis Rheum; 2016 Feb; 45(4 Suppl):S22-7. PubMed ID: 26806184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
